Clinical Trial Update: NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial [Phase 2]

View source ↗

Summary

A Phase 2 trial update for neoadjuvant multi-agent chemotherapy or patritumab deruxtecan with or without endocrine therapy in high-risk HR+/HER2- breast cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Endocrine therapy
• Patritumab Deruxtecan (patritumab deruxtecan)
• neoadjuvant multi-agent chemotherapy

Snippet

Sponsor: SOLTI Breast Cancer Research Group | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING